Evidence map›Paper›PMID 41858573›Full record

ReviewInternational journal of nanomedicine2026

Green Synthesis of Zinc Oxide Nanoparticles and Their Application in Anticancer Drug Delivery - A Review.

Katarzyna Łukowiak, Elżbieta U Stolarczyk

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Polymers · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Katarzyna ŁukowiakSpectrometric Methods Department, National Medicines Institute, Warsaw, 00-725, Poland.ORCID 0000-0002-9156-4199
Elżbieta U StolarczykSpectrometric Methods Department, National Medicines Institute, Warsaw, 00-725, Poland.ORCID 0000-0002-2880-0072

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metal and metal oxide nanoparticles have many promising applications in biomedicine and pharmacy. One of the applications that has been widely studied over the last decade is their use as anticancer drug carriers. This review fills a gap in the literature by concentrating exclusively on biosynthesized zinc oxide nanoparticles (ZnO NPs) for targeted anticancer drug delivery. ZnO NPs have been suggested as a feasible prospect, among other metal-based NPs, because of their unique properties and biocompatible nature. The use of ZnO NPs in drug delivery could reduce the dosage of drugs used for cancer treatment and reduce other side effects, by aiming the specific sites of cancer cells. Green methods of synthesis, with the use of natural products and living organisms, have become very popular in last decades due to their numerous advantages. They are not only eco-friendly and less expensive but they also allow to avoid the waste of energy and receive the NPs with well-defined size and morphology. The biosynthesized ZnO NPs have inherent advantages because they are made with the use of bioactive capping agents. Therefore, they show enhanced performance in drug delivery as they have improved stability, biocompatibility and targeting. This review includes a comparative analysis of synthesis methods and a comprehensive survey of their application as nanocarriers for various anticancer drugs. Their development faces several challenges related to synthesis, toxicity, scalability of the process, and limited understanding of the biochemical mechanisms involved in reduction and stabilization of metal ions through biological agents. Although biosynthesized ZnO NPs show a lot of potential as nanocarriers in laboratory conditions, their use in clinical trials is very challenging and requires collaboration between scientists, process engineers, clinicians and regulatory agencies. However, if these challenges are addressed and treated properly, their full commercial value and widespread applications will be enabled.

Indexed as

Antineoplastic AgentsGreen Chemistry TechnologyMetal NanoparticlesZinc OxideAnimalsDrug CarriersDrug Delivery SystemsHumansNeoplasmsAntineoplastic AgentsDrug CarriersZinc Oxidebiosynthesiscancergreen chemistrynanocarrierstargeted drug deliveryZnO nanoparticles

Identifiers

PMID41858573
PMCPMC12998578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.